Ceritinib
Alectinib
Brigatinib Ensartinib
Trial
ASCEND-1
(Kim et al. Lancet Oncol 2016)
ASCEND-3
(Felip et al. ESMO 2016)
ASCEND-4
(G De Castro et al. WCLC 2016)
AF001JP
(Seto et al. Lancet Oncol 2013)
Phase I/II
(Gettinger et al.
Lancet Oncol 2016)
Phase I/II
Horn et al. ESMO 2016
N
83
124
189
46
8
14
RR
72 %
63.7 %
72.5 %
94 %
100 %
71 %
DCR
74 %
77 %
84.8 %
79.1 %
100 %
85.7 %
PFS
18.4 m
18.4 m
16.6 m
27.7 m
NR
-
1L Second-Generation TKIs
